{"id":576393,"date":"2021-06-28T00:00:00","date_gmt":"2021-06-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0001-2021-biopharma-breast-cancer-current-treatment-eu5-2021\/"},"modified":"2026-04-15T09:50:59","modified_gmt":"2026-04-15T09:50:59","slug":"cutron0001-2021-biopharma-breast-cancer-current-treatment-eu5-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0001-2021-biopharma-breast-cancer-current-treatment-eu5-2021\/","title":{"rendered":"Breast Cancer | Current Treatment | EU5 | 2021"},"content":{"rendered":"<p>Insights on EU5 medical oncologists&#8217; prescribing practices and key factors influencing their treatment decisions for HR-positive\/HER2-negative breast cancer patients.<\/p>\n","protected":false},"template":"","class_list":["post-576393","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-current-treatment","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576393\/revisions"}],"predecessor-version":[{"id":577569,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576393\/revisions\/577569"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=576393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}